From TekinHealthHealthcare Tech Field Notes

DeepHealth, a RadNet company, received FDA 510(k) clearance for Chest XRay, formerly ChestView. The computer-aided detection tool finds and localizes suspected lung nodules, consolidation, mediastinal and hilar abnormalities, and pleural abnormalities including pneumothorax. It is reported to be one of the first FDA-cleared chest X-ray AI products built on a foundation model. The company says the CE-marked European version analyzes more than 2.8 million exams a year.

Why it's notable: Foundation-model imaging AI can add new findings faster than single-purpose algorithms. This clearance shows the FDA is accepting that design for one of the most common exams in medicine.

The FDA granted De Novo authorization to Powerful Medical's PMcardio Queen of Hearts, an AI model that reads 12-lead ECGs for signs of urgent acute coronary syndrome, including STEMI and STEMI equivalents, and alerts clinicians to suspected cases. STAT reported the authorization on September 11 and the company announced it on September 15. The company says the model is backed by more than 20 peer-reviewed studies covering over 40,000 patients, found about twice as many heart attacks as standard care with up to five times fewer false positives, and is already used across more than 150 hospital locations, mostly in Europe.

Why it's notable: Many heart attacks caused by a fully blocked artery don't meet standard STEMI criteria on the ECG. A tool that flags them could get more of these patients to the cath lab faster. De Novo authorizations are rare, and this one creates a new FDA device category for AI ECG models that detect acute, life-threatening heart conditions.

CMS approved a New Technology Add-on Payment (NTAP) for Aidoc's CARE Body CT Multi-Triage. The FDA-cleared software flags suspected urgent findings on contrast and non-contrast CT of the chest, abdomen and pelvis. Holland & Knight says this is the first NTAP CMS has granted for an AI-enabled diagnostic tool. Starting October 1, 2026, hospitals can receive the add-on for eligible Medicare fee-for-service inpatient cases for three years, with a reported maximum of $137.53 per case.

Why it's notable: How to pay for AI has been one of the main barriers to hospitals adopting imaging AI. A Medicare add-on for an AI triage tool gives other vendors and hospital finance teams a path to follow.

Twelve US health systems announced a Diagnostic AI Consortium with Aidoc on August 11, 2026. Members are Advocate Health, Cedars-Sinai, Hartford HealthCare, Houston Methodist, Mercy, Mount Sinai, Northwell Health, Northwestern Medicine, Sutter Health, UF Health, University Hospitals of Cleveland and WellSpan Health, which together care for nearly 20 million patients a year. The group plans to co-design AI-assisted diagnostic workflows, measure their effect on safety, quality and time to diagnosis across member sites, and agree on shared evaluation and governance practices. Aidoc is supplying the technology through its CARE foundation model and aiOS platform, and the group expects to share its first results in 2027.

Why it's notable: Health systems usually evaluate imaging AI one site at a time. Here a dozen large systems are pooling evidence on whether it actually speeds diagnosis, which could set the standards other hospitals use when they buy and govern these tools.

RadNet subsidiary DeepHealth received FDA 510(k) clearance on July 30, 2026 for DeepHealth Breast Ultrasound, software that automates lesion detection, characterization and reporting. In a multi-reader study with 16 U.S. board-certified radiologists, the company reports more than 98% lesion localization accuracy, an 8% gain in cancer-detection sensitivity and a 37% cut in interpretation time. It is commercially available in the U.S., and DeepHealth expects to roll it out across RadNet's imaging centers by year end.

Why it's notable: Breast ultrasound is labor-intensive and highly operator-dependent, and it is used more often for women with dense breasts. A cleared tool that drafts findings and reports could ease radiologist workload in breast imaging.

Tempus AI agreed on July 20, 2026 to acquire Personalis for $16.25 per share, valuing the deal at about $1.5 billion. The deal adds Personalis's NeXT Personal minimal residual disease (MRD) blood test, which Tempus has sold under a partnership since 2023, to its AI-driven precision oncology platform. The deal is mainly in stock, with Tempus able to pay up to half in cash. It needs Personalis shareholder and regulatory approval and is expected to close in late 2026 or early 2027.

Why it's notable: MRD testing, which tracks cancer recurrence from blood, is becoming part of routine oncology follow-up. The deal puts one of the more sensitive tests on the market under a large AI and genomic data company that oncologists already order from.

On June 25, 2026, Aidoc said the FDA granted Breakthrough Device Designation to First Read, software that analyzes chest radiographs and writes a draft radiology report for a radiologist to review and sign. The designation covers four life-threatening findings, and the company says the tool is designed to report on more than 100 findings. It is built on Aidoc's CARE foundation model. Breakthrough designation speeds up FDA review but is not a clearance, and First Read is not yet on the market. It is Aidoc's second breakthrough designation in under a year.

Why it's notable: This is one of the first AI tools meant to write the radiology report itself, not just flag a finding, to enter an expedited FDA pathway. That points to how imaging backlogs and report turnaround times may be handled.

Roche signed a definitive agreement on May 7, 2026 to acquire Boston-based PathAI for $750 million upfront plus up to $300 million in milestone payments. PathAI makes AI models that analyze patient tissue samples and software for running digital pathology labs; Labcorp had expanded its use of the platform across its anatomic pathology labs earlier in 2026. The two companies had worked together since 2021, including on AI-based companion diagnostics. Roche said PathAI would join its Diagnostics division, with closing expected in the second half of 2026 pending antitrust and regulatory approval.

Why it's notable: One of the largest diagnostics companies is buying an AI pathology platform outright rather than partnering, a sign that AI-assisted slide review is moving into the standard lab product line that hospitals and reference labs buy.

On April 1, 2026, the FDA denied a petition from Sydney-based Harrison.ai. The company wanted developers that already had a 510(k) clearance to be able to market new AI tools in four radiology categories without premarket review, including triage (CADt), detection and diagnosis (CADe/CADx) software and medical image analyzers. The agency said clearing one device does not show that a company's processes will produce safe future devices, and that postmarket monitoring cannot replace premarket review. It pointed developers to predetermined change control plans instead. The FDA finalized the denial in the Federal Register on September 17, 2026.

Why it's notable: New radiology AI tools, and major new versions of them, will still need FDA review before they reach health systems. Buyers should check which software version is actually cleared.

Imaging center operator RadNet said on March 2, 2026 that it is acquiring Paris-based Gleamer for up to €230 million in cash: €215 million upfront plus €15 million in milestones. Gleamer will be folded into RadNet's DeepHealth AI unit. Gleamer has four FDA-cleared products, including BoneView for fracture detection on X-rays, CT lung nodule detection and MRI multiple sclerosis lesion detection. It is forecast to reach about $30 million in annual recurring revenue in 2026. RadNet says the deal makes DeepHealth the largest radiology clinical AI provider worldwide.

Why it's notable: Radiology AI is consolidating. Hospitals and imaging groups buying point tools for X-ray, CT and MRI may increasingly buy them from one platform owned by a large imaging provider.

On February 17, 2026, Danaher agreed to buy Masimo for $180 a share in cash, an enterprise value of about $9.9 billion. Masimo makes pulse oximetry and patient-monitoring equipment used mainly in hospitals. It will run as a standalone business in Danaher's diagnostics segment, next to Radiometer, Cepheid, Beckman Coulter and Leica Biosystems. Danaher says it expects more than $125 million a year in cost savings and more than $50 million a year in added sales from the combination by the fifth year. The deal closed on June 10, 2026.

Why it's notable: A monitoring brand found at most hospital bedsides now belongs to one of the largest diagnostics companies. This sets Danaher up to compete directly with Medtronic in pulse oximetry and may change how hospitals buy monitors and blood-gas equipment together.

The FDA qualified PathAI's AIM-MASH AI Assist through its Drug Development Tool biomarker qualification program. The agency calls it the first AI drug development tool it has qualified. The cloud-based software scores liver biopsy images for steatosis, ballooning, lobular inflammation and fibrosis stage in MASH clinical trials, using the NASH Clinical Research Network system. Pathologists review and accept or reject every score. PathAI says the model was trained on more than 100,000 annotations from 59 pathologists and 5,900 biopsies from six MASH trials.

Why it's notable: In MASH trials, several pathologists usually read each biopsy by hand, and their scores often disagree. The FDA says a qualified AI reader could make that assessment more consistent and cut the time and cost of developing MASH drugs. It is also the first regulatory path for using AI to measure a trial endpoint.

On December 5, 2025, Freenome agreed to merge with Perceptive Capital Solutions Corp, a special purpose acquisition company (SPAC). The deal was expected to bring in about $330 million, including a $240 million private investment led by Perceptive Advisors and RA Capital. Freenome's SimpleScreen blood test for colorectal cancer was under FDA review, with a decision expected in mid-2026. Exact Sciences paid $75 million up front in August 2025 for US rights to the test, and Roche holds rights outside the US. The merger closed on July 20, 2026, with about $310 million in gross proceeds, and Freenome began trading on Nasdaq as FRNM.

Why it's notable: Blood-based colorectal cancer screening could reach patients who skip colonoscopy and stool tests. This deal funds one of the main contenders as it heads toward an FDA decision and a US launch through Exact Sciences.

Abbott agreed to acquire Exact Sciences for $105 a share in cash, an equity value of about $21 billion and roughly $23 billion including debt. Exact Sciences makes the Cologuard at-home colorectal cancer screening test, the Oncotype DX breast cancer test, and liquid biopsy tests for multi-cancer early detection and molecular residual disease. Abbott said Exact would bring in more than $3 billion in revenue in 2025 and raise Abbott's diagnostics sales above $12 billion a year. The deal closed on March 23, 2026.

Why it's notable: One of the largest diagnostics makers now owns the most widely used at-home colon cancer screening test and a set of newer blood-based cancer tests. That could affect how these tests are sold to clinics and paid for.

GE HealthCare agreed to acquire Intelerad, a Montreal-based maker of cloud PACS, image-sharing and imaging workflow software, for $2.3 billion in cash. Intelerad's business is concentrated in outpatient and ambulatory imaging. GE HealthCare expects about $270 million in Intelerad revenue in the first full year, roughly 90% of it recurring. GE HealthCare said the deal supports its goal of tripling its cloud-enabled products by 2028. The acquisition closed in March 2026.

Why it's notable: A major scanner maker is buying its way into cloud imaging software for outpatient imaging centers and specialty clinics. That will affect which PACS and imaging AI tools those sites get offered.